Evidence map›Paper›PMID 35760847›Full record

ArticleCommunications biology2022

TAS-Seq is a robust and sensitive amplification method for bead-based scRNA-seq.

Shigeyuki Shichino, Satoshi Ueha, Shinichi Hashimoto, Tatsuro Ogawa, Hiroyasu Aoki, Bin Wu, Chang-Yu Chen, Masahiro Kitabatake, Noriko Ouji-Sageshima, Noriyoshi Sawabata and 10 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Egr2 drives the differentiation of Ly6CCommunications biology · 2024
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Shigeyuki ShichinoDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences, Tokyo University of Science, Chiba, Japan.ORCID 0000-0002-1683-2448
Satoshi UehaDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Shinichi HashimotoDepartment of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.ORCID 0000-0002-1223-2349
Tatsuro OgawaDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Hiroyasu AokiDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Bin WuDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Chang-Yu ChenDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Masahiro KitabatakeDepartment of Immunology, Nara Medical University, Nara, Japan.
Noriko Ouji-SageshimaDepartment of Immunology, Nara Medical University, Nara, Japan.
Noriyoshi SawabataDepartment of Thoracic and Cardio-Vascular Surgery, Nara Medical University, Nara, Japan.
Takeshi KawaguchiDepartment of Thoracic and Cardio-Vascular Surgery, Nara Medical University, Nara, Japan.
Toshitugu OkayamaNational Institute of Genetics, Shizuoka, Japan.
Eiji SugiharaResearch and Development Center for Precision Medicine, University of Tsukuba, Ibaragi, Japan.ORCID 0000-0002-3233-1045
Shigeto HontsuDepartment of Respiratory Medicine, Nara Medical University, Nara, Japan.
Toshihiro ItoDepartment of Immunology, Nara Medical University, Nara, Japan.
Yasunori IwataDivision of Infection Control, Kanazawa University Hospital, Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.
Takashi WadaDivision of Infection Control, Kanazawa University Hospital, Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.
Kazuho IkeoNational Institute of Genetics, Shizuoka, Japan.
Taka-Aki SatoResearch and Development Center for Precision Medicine, University of Tsukuba, Ibaragi, Japan.
Kouji MatsushimaDivision of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences, Tokyo University of Science, Chiba, Japan. koujim@rs.tus.ac.jp.ORCID 0000-0003-1056-171X
Tokyo University of Science · JPNara Medical University · JPKanazawa University Hospital · JPNational Institute of Genetics · JPFujita Health University · JPUniversity of Tsukuba · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-cell RNA-sequencing (scRNA-seq) is valuable for analyzing cellular heterogeneity. Cell composition accuracy is critical for analyzing cell-cell interaction networks from scRNA-seq data. However, droplet- and plate-based scRNA-seq techniques have cell sampling bias that could affect the cell composition of scRNA-seq datasets. Here we developed terminator-assisted solid-phase cDNA amplification and sequencing (TAS-Seq) for scRNA-seq based on a terminator, terminal transferase, and nanowell/bead-based scRNA-seq platform. TAS-Seq showed high tolerance to variations in the terminal transferase reaction, which complicate the handling of existing terminal transferase-based scRNA-seq methods. In murine and human lung samples, TAS-Seq yielded scRNA-seq data that were highly correlated with flow-cytometric data, showing higher gene-detection sensitivity and more robust detection of important cell-cell interactions and expression of growth factors/interleukins in cell subsets than 10X Chromium v2 and Smart-seq2. Expanding TAS-Seq application will improve understanding and atlas construction of lung biology at the single-cell level.

Indexed as

Gene Expression ProfilingSingle-Cell AnalysisAnimalsDNA, ComplementaryHumansMiceSequence Analysis, RNATransferasesDNA, ComplementaryTransferases

Identifiers

PMID35760847
PMCPMC9245575
OpenAlexW4283706506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.